{
  "alleleExist":true,
  "dataVersion":"v4.5",
  "diagnosticImplications":[],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"EGFR, a receptor tyrosine kinase, is altered by amplification and/or mutation in lung and brain cancers among others.",
  "highestDiagnosticImplicationLevel":null,
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":true,
  "lastUpdate":"03/21/2019",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "29533785"
      ]
    },
    "description":"The EGFR P596L mutation lies in the extracellular domain of the protein. Expression of this mutation in Ba/F3 and MCF10A cell lines demonstrated it is likely activating as measured by increased cell viability compared to wildtype EGFR (PMID: 29533785).",
    "knownEffect":"Likely Gain-of-function"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"P596L",
    "alterationType":null,
    "consequence":null,
    "entrezGeneId":1956,
    "hgvs":null,
    "hugoSymbol":"EGFR",
    "id":null,
    "proteinEnd":null,
    "proteinStart":null,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":true,
  "variantSummary":"The EGFR P596L mutation is likely oncogenic.",
  "vus":false
}